Sarepta Therapeutics Inc
SRPT15.910USD
-0.510-3.11%
Fechamento 08/01, 16:00（ET）Cotações atrasadas em 15 min
1.56BValor de mercado
PerdaP/L TTM
Mais detalhes de Sarepta Therapeutics Inc Empresa
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy (Duchenne) and is developing potential therapeutic candidates for a range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. The Company has developed and commercialized four approved products for the treatment of Duchenne: EXONDYS 51 (eteplirsen), Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53), AMONDYS 45 (casimersen) Injection (AMONDYS 45), and ELEVIDYS. Its pipeline includes over 40 programs at various stages of discovery, pre-clinical and clinical development.
Informações da empresa
Código da empresaSRPT
Nome da EmpresaSarepta Therapeutics Inc
Data de listagemJun 04, 1997
Fundado em2013
CEOMr. Douglas S. (Doug) Ingram, Esq., J.D.
Número de funcionários1372
Tipo de títulosOrdinary Share
Fim do ano fiscalJun 04
Endereço215 First Street
CidadeCAMBRIDGE
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal02142
Telefone16172744000
Sitehttps://www.sarepta.com/
Código da empresaSRPT
Data de listagemJun 04, 1997
Fundado em2013
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Richard J. (Rick) Barry
Mr. Richard J. (Rick) Barry
Independent Director
Independent Director
3.21M
+1.02%
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Chief Executive Officer
Chief Executive Officer
390.31K
--
Dr. Louise Rodino-Klapac, Ph.D.
Dr. Louise Rodino-Klapac, Ph.D.
President - Research and Development and Technical Operations
President - Research and Development and Technical Operations
57.60K
+21.66%
Mr. Ian Michael Estepan
Mr. Ian Michael Estepan
President, Chief Operating Officer
President, Chief Operating Officer
45.59K
+0.22%
Dr. Hans Lennart Rudolf Wigzell, M.D., Ph.D.
Dr. Hans Lennart Rudolf Wigzell, M.D., Ph.D.
Independent Director
Independent Director
22.84K
-2.30%
Mr. Dallan Murray
Mr. Dallan Murray
Executive Vice President, Chief Customer Officer
Executive Vice President, Chief Customer Officer
21.18K
-44.29%
Cristin Rothfuss
Cristin Rothfuss
Executive Vice President, General Counsel, Corporate Secretary
Executive Vice President, General Counsel, Corporate Secretary
19.15K
+38.59%
Mr. Bilal Arif
Mr. Bilal Arif
Executive Vice President , Chief Technical Operations Officer
Executive Vice President , Chief Technical Operations Officer
16.42K
-16.76%
Mr. Ryan Wong
Mr. Ryan Wong
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
--
--
Ms. Deirdre Connelly
Ms. Deirdre Connelly
Independent Director
Independent Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Richard J. (Rick) Barry
Mr. Richard J. (Rick) Barry
Independent Director
Independent Director
3.21M
+1.02%
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Chief Executive Officer
Chief Executive Officer
390.31K
--
Dr. Louise Rodino-Klapac, Ph.D.
Dr. Louise Rodino-Klapac, Ph.D.
President - Research and Development and Technical Operations
President - Research and Development and Technical Operations
57.60K
+21.66%
Mr. Ian Michael Estepan
Mr. Ian Michael Estepan
President, Chief Operating Officer
President, Chief Operating Officer
45.59K
+0.22%
Dr. Hans Lennart Rudolf Wigzell, M.D., Ph.D.
Dr. Hans Lennart Rudolf Wigzell, M.D., Ph.D.
Independent Director
Independent Director
22.84K
-2.30%
Mr. Dallan Murray
Mr. Dallan Murray
Executive Vice President, Chief Customer Officer
Executive Vice President, Chief Customer Officer
21.18K
-44.29%
Detalhamento da receita
Moeda: USDAtualizado em: dom, 6 de jul
Moeda: USDAtualizado em: dom, 6 de jul
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
Por EmpresaUSD
Nome
Receita
Proporção
ELEVIDYS
374.99M
50.34%
PMO Products
236.54M
31.76%
collaboration and other
133.33M
17.90%
Por RegiãoUSD
Nome
Receita
Proporção
United States
560.81M
75.29%
Rest of World
50.71M
6.81%
Por Empresa
Por Região
Por EmpresaUSD
Nome
Receita
Proporção
ELEVIDYS
374.99M
50.34%
PMO Products
236.54M
31.76%
collaboration and other
133.33M
17.90%
Distribuição de ações
Atualizado em: dom, 27 de jul
Atualizado em: dom, 27 de jul
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Capital International Investors
9.22%
The Vanguard Group, Inc.
9.17%
BlackRock Institutional Trust Company, N.A.
9.06%
D. E. Shaw & Co., L.P.
5.15%
State Street Global Advisors (US)
4.14%
Other
63.27%
Investidores
Investidores
Proporção
Capital International Investors
9.22%
The Vanguard Group, Inc.
9.17%
BlackRock Institutional Trust Company, N.A.
9.06%
D. E. Shaw & Co., L.P.
5.15%
State Street Global Advisors (US)
4.14%
Other
63.27%
Tipos de investidores
Investidores
Proporção
Investment Advisor
45.71%
Investment Advisor/Hedge Fund
28.79%
Hedge Fund
14.66%
Individual Investor
4.42%
Research Firm
3.31%
Bank and Trust
1.12%
Sovereign Wealth Fund
1.09%
Pension Fund
1.08%
Venture Capital
0.33%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
1025
94.29M
95.95%
-13.91M
2025Q1
1077
102.36M
104.40%
-6.43M
2024Q4
1057
102.62M
105.91%
-1.51M
2024Q3
1027
96.14M
100.83%
-6.90M
2024Q2
997
94.21M
99.66%
-1.44M
2024Q1
932
88.31M
94.10%
-6.68M
2023Q4
926
87.42M
93.47%
-6.42M
2023Q3
916
88.86M
95.27%
-4.43M
2023Q2
931
87.46M
93.91%
-4.38M
2023Q1
946
86.41M
92.84%
-2.26M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Capital International Investors
9.06M
9.22%
+363.63K
+4.18%
Mar 31, 2025
The Vanguard Group, Inc.
9.01M
9.17%
-59.02K
-0.65%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
8.90M
9.06%
-32.03K
-0.36%
Mar 31, 2025
State Street Global Advisors (US)
4.07M
4.14%
-1.39K
-0.03%
Mar 31, 2025
Janus Henderson Investors
3.36M
3.42%
-963.48K
-22.26%
Mar 31, 2025
Barry (Richard J)
3.21M
3.27%
+32.60K
+1.02%
May 16, 2025
Avoro Capital Advisors LLC
2.67M
2.72%
+119.28K
+4.67%
Mar 31, 2025
Wellington Management Company, LLP
2.65M
2.69%
+577.85K
+27.93%
Mar 31, 2025
Farallon Capital Management, L.L.C.
2.34M
2.38%
-523.68K
-18.28%
Mar 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: dom, 6 de jul
Atualizado em: dom, 6 de jul
Nome
Proporção
Global X Genomics & Biotechnology ETF
2.7%
First Trust NYSE Arca Biotechnology Index Fund
2.31%
iShares Neuroscience and Healthcare ETF
1.71%
WisdomTree BioRevolution Fund
0.92%
Virtus LifeSci Biotech Products ETF
0.91%
Harbor Human Capital Factor Unconstrained ETF
0.87%
VanEck Biotech ETF
0.79%
Tema Neuroscience and Mental Health ETF
0.72%
SPDR S&P Biotech ETF
0.66%
Invesco S&P MidCap 400 Pure Growth ETF
0.54%
Ver Mais
Global X Genomics & Biotechnology ETF
Proporção2.7%
First Trust NYSE Arca Biotechnology Index Fund
Proporção2.31%
iShares Neuroscience and Healthcare ETF
Proporção1.71%
WisdomTree BioRevolution Fund
Proporção0.92%
Virtus LifeSci Biotech Products ETF
Proporção0.91%
Harbor Human Capital Factor Unconstrained ETF
Proporção0.87%
VanEck Biotech ETF
Proporção0.79%
Tema Neuroscience and Mental Health ETF
Proporção0.72%
SPDR S&P Biotech ETF
Proporção0.66%
Invesco S&P MidCap 400 Pure Growth ETF
Proporção0.54%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
